A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $19 to $21
Arcutis Biotherapeutics Says ZORYVE Foam 0.3% Linked To Adverse Reactions Including Headache, Nausea, And Diarrhea, With Flammability Risk And Contraindications For Liver-Impaired Patients Highlighted In Safety Profile Under FDA Review
Arcutis Biotherapeutics: Zoryve Foam Treatment Resulted in Major Improvements
Arcutis Biotherapeutics Reports Positive Phase 3 Study Results for Investigational ZORYVE Foam 0.3% in Treating Scalp and Body Psoriasis
Arcutis Announces Publication of Positive Data From ARRECTOR Trial Evaluating ZORYVE (Roflumilast) Foam 0.3% in Individuals With Psoriasis in Journal of American Medical Association Dermatology
Analysts Are Bullish on These Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Praxis Precision Medicines (PRAX)
Earnings Call Summary | Arcutis Biotherapeutics(ARQT.US) Q1 2025 Earnings Conference
Arcutis Outlines Growth Potential With ZORYVE Expansions and Market Penetration
Arcutis Biotherapeutics Stock Falls Despite Q1 Revenue Beat
ARCUTIS BIOTHERAPEUTICS Earnings Results: $ARQT Reports Quarterly Earnings
Arcutis Biotherapeutics Reports Q1 EPS (20c), Consensus (21c)
Arcutis Biotherapeutics | 10-Q: Quarterly report
Arcutis Biotherapeutics | 8-K: Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Earnings Flash (ARQT) Arcutis Biotherapeutics Reports Q1 Revenue $65.8M, Vs. FactSet Est of $62.2M
Express News | Arcutis Biotherapeutics Inc - Pdufa Action Date for Zoryve Foam Set for May 22, 2025
Press Release: Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Express News | Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Arcutis Biotherapeutics 1Q Loss/Shr 20c >ARQT
Arcutis Biotherapeutics 1Q Loss $25.1M >ARQT
Express News | Arcutis Biotherapeutics Q1 Operating Expenses USD 90.375 Million